A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS.
Fathi AT, et al. Among authors: faderl s.
Blood. 2018 Sep 13;132(11):1125-1133. doi: 10.1182/blood-2018-03-841171. Epub 2018 Jul 25.
Blood. 2018.
PMID: 30045838
Free PMC article.
Clinical Trial.